Pancreatic Acinar Cell Carcinoma clinical trials at UCSF
1 research study open to eligible people
Pancreatic acinar cell carcinoma is a rare cancer that starts in the pancreas. UCSF is running clinical trials to improve treatments for this cancer. One study is looking at how well a combination of three drugs works for patients with certain genetic changes.
PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
open to eligible people ages 18 years and up
This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.
San Francisco, California and other locations
Our lead scientists for Pancreatic Acinar Cell Carcinoma research studies include Andrew H. Ko.
Last updated: